RxDoctor Payments Data

Laszlo Szollas, MD

Interventional Pain Medicine · East Stroudsburg, PANPI 1790880003

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,329 of the $3,184 with a category attached, or 73.1%. 25 manufacturers reported payments, led by Stryker at 31.2% of the total. That places this record below the midpoint for interventional pain medicine clinicians in PA, where the typical reported total is $2,714.

$3,184in general payments, 2019–2025

Across 173 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$994
  • Boston Scientific$606
  • Medtronic$327
  • Collegium Pharmaceutical, Inc.$189
  • Endo Pharmaceuticals Inc.$181
  • Nevro Corp.$173
  • plus $715 from 19 others

What the payments were for

  • Travel & lodging$85527%
  • Food & beverage$2,32973%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,184 in reported general payments places this provider in the 50th percentile of 59 interventional pain medicine providers in Pennsylvania.

See all interventional pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$562,885
Medicare patients
488
Services billed
29,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl53$34,919
OxycontinOxycodone Hcl43$24,167
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen554$13,403
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen536$12,223
MovantikNaloxegol Oxalate23$9,405
Buprenorphine30$6,866
Gabapentin468$6,611
Celecoxib173$5,059
Lidocaine47$4,804
Acetaminophen-CodeineAcetaminophen With Codeine221$4,005
Cyclobenzaprine Hcl240$3,958
Morphine Sulfate ErMorphine Sulfate137$3,856
Morphine Sulfate120$3,724
Tramadol Hcl436$3,295
Pregabalin267$3,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$189$34,91953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 59 interventional pain medicine providers in Pennsylvania.

Other interventional pain medicine in East Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →